Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selvigaltin + Dara-KD in Relapsed/Refractory Multiple Myeloma
NCT07082270Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selvigaltin in multiple myeloma (MM), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of dose limiting toxicities up to 28 days, Maximum tolerated dose up to 28 days and 1 more. Planned start Apr 2026; status: withdrawn.
02
Drugs
selvigaltin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07082270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082270.